Evaluation of a targeted nanobubble ultrasound contrast agent for potential tumor imaging

Targeted nanobubbles have been reported to improve the contrast effect of ultrasound imaging due to the enhanced permeation and retention effects at tumor vascular leaks. In this work, the contrast enhancement abilities and the tumor targeting potential of a self-made VEGFR2-targeted nanobubble ultrasound contrast agent was evaluated in-vitro and in-vivo. Size distribution and zeta potential were assessed. Then the contrast-enhanced ultrasound imaging of the VEGFR2 targeted nanobubbles were evaluated with a custom-made experimental apparatus and in normal Wistar rats. Finally, the in-vivo tumor-targeting ability was evaluated on nude mice with subcutaneous tumor. The results showed that the target nanobubbles had uniform distribution with the average diameter of 208.1 nm, polydispersity index (PDI) of 0.411, and zeta potential of -13.21 mV. Significant contrast enhancement was observed in both in-vitro and in-vivo ultrasound imaging, demonstrating that the self-made target nanobubbles can enhance the contrast effect of ultrasound imaging efficiently. Targeted tumor imaging showed less promising result, due to the fact that the targeted nanobubbles arriving and permeating through tumor vessels were not many enough to produce significant enhancement. Future work will focus on exploring new imaging algorithm which is sensitive to targeted nanobubbles, so as to correctly detect the contrast agent, particularly at a low bubble concentration.

[1]  F. Forsberg,et al.  Contrast-enhanced ultrasound for molecular imaging of angiogenesis , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  P. Dayton,et al.  Introduction to the special issue on ultrasound contrast agents and targeted drug delivery , 2013 .

[3]  Sanjiv S Gambhir,et al.  Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. , 2008, Radiology.

[4]  Ping Wang,et al.  Nanobubbles for enhanced ultrasound imaging of tumors , 2012, International journal of nanomedicine.

[5]  J. Willmann,et al.  Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. , 2011, Radiology.

[6]  S. Skinner,et al.  Microvascular architecture of experimental colon tumors in the rat. , 1990, Cancer research.

[7]  J. Ophir,et al.  IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control , 2008, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.

[8]  Zhanwen Xing,et al.  The fabrication of novel nanobubble ultrasound contrast agent for potential tumor imaging , 2010, Nanotechnology.

[9]  K. Hoyt,et al.  Model system using controlled receptor expression for evaluating targeted ultrasound contrast agents. , 2011, Ultrasound in medicine & biology.

[10]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[11]  V. Dilsizian,et al.  Delayed recovery of fatty acid metabolism after transient myocardial ischemia: A potential imaging target for “ischemic memory” , 2007, Current cardiology reports.

[12]  Y. Liu,et al.  Efficacy of contrast-enhanced US and magnetic microbubbles targeted to vascular cell adhesion molecule-1 for molecular imaging of atherosclerosis. , 2011, Radiology.

[13]  S A Wickline,et al.  Targeted ultrasonic contrast agents for molecular imaging and therapy. , 2003, Progress in cardiovascular diseases.

[14]  Samuel A Wickline,et al.  Targeted ultrasonic contrast agents for molecular imaging and therapy. , 2001, Current problems in cardiology.

[15]  Emilio Quaia,et al.  Assessment of tissue perfusion by contrast-enhanced ultrasound , 2011, European Radiology.

[16]  Sergio Uzzau,et al.  Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel ultrasound contrast agents. , 2011, Molecular pharmaceutics.